From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) that can change the behavior of immune cells so they protect dopamine-producing cells rather than attacking them.[1] The drug is being studied for its potential use for Parkinson's disease.[2]


LBT-3627 specifically targets the VIP2 receptor, unlike VIP.[3] The drug also affects microglia.[1] In addition, LBT-3627 is more durable in the body compared to VIP.[4]

History and development[edit]

Scientists at the University of Nebraska Medical Center and Longevity Biotech, Inc. first demonstrated the use of the drug in mouse models.[2][4]

A phase I trial for humans was planned for 2017,[4] but as of 2018 it was still in the preclinical development stage.[5]


  1. ^ a b Paddock, Catharine (December 17, 2015). "New drug that protects dopamine cells raises treatment hope for Parkinson's". Medical News Today. Retrieved December 18, 2015.
  2. ^ a b "Pioneering Neuroprotective Results Achieved in Parkinson's Disease Preclinical Studies". PR Newswire. December 16, 2015. Retrieved December 21, 2015.
  3. ^ Azevedo, Margarida (December 21, 2015). "New Drug Candidate Shows Promise in Animal Model of Parkinson's". Parkinson's News Today. Retrieved December 21, 2015.
  4. ^ a b c Block, Jonathan (December 17, 2015). "Drug That Protects Dopamine Cells Eyed as Parkinson's Treatment". Phychiatry Advisor. Retrieved December 21, 2015.
  5. ^ "Research programme: peptide-based therapeutics - Longevity Biotech". AdisInsight. January 8, 2018. Highest Development Phases: Preclinical : Neurological disorders; Type 2 diabetes mellitus